Canadian Cancer Trials Group Bulletins

General


Canadian Cancer Trials Group awarded $23.5M over 5 years

Canadian Cancer Society supports high quality, innovative clinical trial research

The Canadian Cancer Society (CCS) has renewed its commitment to the Canadian Cancer Trials Group (CCTG) through a major funding award of $23.5 million over 5 years. This generous funding allows CCTG to continue its world-class cancer clinical trials research.

"Since 1980, the Canadian Cancer Society has supported the great work at CCTG by investing nearly $130 million, which is the largest investment in our research portfolio," says Lynne Hudson, CCS President and CEO. "We continue to support CCTG because of their track record of success. They have set the bar for the safest, most effective cancer clinical trials research in Canada and improved the worldwide standard of care for patients with cancer."

"The Canadian Cancer Society's reinvestment in CCTG is fundamental to its ability to improve patient outcomes for Canadians," says Richard Reznick, Dean of the Faculty of Health Sciences at Queen's University. "The CCTG team have proven themselves as world-renowned scientists, and we are thrilled to have partners like CCS championing this cutting-edge research and innovation network."

The decision to award the funding was supported by a comprehensive review process. An international multi-disciplinary scientific team independently evaluated the group's processes, strengths, weaknesses and potential future impact.

Read more:

Press release http://www.newswire.ca/news-releases/canadian-cancer-trials-group-awarded-235m-over-5-years-620904143.html

Whig Standard Article http://www.thewhig.com/2017/05/01/cancer-society-gives-trials-group-235m